Auris Medical Holding, a biotech developing treatments for inner ear disorders, filed on Monday with the SEC to raise up to $86 million in an initial public offering. The Switzerland-based company plans to list on the NASDAQ under the symbol EARS. Jefferies and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
